NASDAQ: TNGXTango Therapeutics Inc Stock
$1.38+0.09 (+6.98%)
Updated Apr 21, 2025
TNGX Price
$1.38
Fair Value Price
N/A
Market Cap
$149.19M
52 Week Low
$1.11
52 Week High
$12.02
P/E
-1.16x
P/B
0.75x
P/S
8.02x
PEG
N/A
Dividend Yield
N/A
Revenue
$42.07M
Earnings
-$130.30M
Gross Margin
100%
Operating Margin
-309.24%
Profit Margin
-309.7%
Debt to Equity
0.59
Operating Cash Flow
-$132M
Beta
1.07
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TNGX Overview
Tango Therapeutics Incorporated is a biotechnology company that develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 to treat cancers with methylthioadenosine phosphorylase deletions. The company is also developing Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers, and Target 3 for STK11-mutant cancers. Tango Therapeutics was founded in 2017 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TNGX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TNGX
Ranked#388 of 462
Ranked#388 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important TNGX news, forecast changes, insider trades & much more!
TNGX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TNGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TNGX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TNGX is good value based on its book value relative to its share price (0.75x), compared to the US Biotechnology industry average (4.04x)
P/B vs Industry Valuation
TNGX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TNGX due diligence checks available for Premium users.
Valuation
TNGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.16x
Industry
-184.27x
Market
27.14x
TNGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.75x
Industry
4.04x
TNGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TNGX's financial health
Profit margin
Revenue
$4.1M
Net Income
-$37.7M
Profit Margin
-915%
TNGX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TNGX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$316.5M
Liabilities
$117.0M
Debt to equity
0.59
TNGX's short-term assets ($266.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TNGX's short-term assets ($266.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TNGX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TNGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$36.6M
Investing
$52.1M
Financing
$969.0k
TNGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TNGX vs Biotech Stocks
Tango Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.